Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6766787 | 0.83 | NPY1R (0.39) | NPY1RNPY5R | |
| SCHEMBL6764812 | 0.79 | NPY1R (0.42) | NPY1RNPY5R | |
| SCHEMBL6767361 | 0.78 | CFD (0.39) | NPY1RNPY5R | |
| SCHEMBL7014517 | 0.78 | — | — | |
| SCHEMBL7006731 | 0.77 | CFD (0.39) | — | |
| SCHEMBL24177242 | 0.72 | ADRA1D (0.68) | — | |
| SCHEMBL6765510 | 0.71 | — | — | |
| SCHEMBL11044249 | 0.71 | ADRA1A (0.61) | — | |
| Water SCHEMBL11048144 | 0.70 | ADRA1A (0.60) | — | |
| Water SCHEMBL11048140 | 0.70 | ADRA1A (0.60) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040034032-A1 | Quinoline and quinazoline compounds useful in therapy | PFIZER INC | 2004-02-19 | — | — | US | disclosed |
| US-6649620-B2 | Particularly in the treatment of benign prostatic hyperplasia. | PFIZER INC. | 2003-11-18 | — | — | US | disclosed |
| US-20030045525-A1 | Quinoline and quinazoline compounds useful in therapy | COLLIS ALAN JOHN (GB) | 2003-03-06 | — | — | US | disclosed |
| EP-0875506-B1 | Quinoline and quinazoline compounds useful in therapy | PFIZER LTD (GB) | 2003-02-26 | — | — | EP | disclosed |
| EP-0875506-A1 | Quinoline and quinazoline compounds useful in therapy | Pfizer Limited (GB) | 1998-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045525-A1 | Quinoline and quinazoline compounds useful in therapy | NQO2, LPXN, BPHL | NPY1R 428/4885NPY5R 659/4885 |
| US-20040034032-A1 | Quinoline and quinazoline compounds useful in therapy | NQO2, LPXN, SDHA | NPY1R 439/4885NPY5R 674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.